Business
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation
About this update from Nektar Therapeutics
[{"type":"text","content":"\n SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.\n \n \n \n \n \n \n \n \n Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here\n \n The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.\n If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.\n \n About Nektar Therapeutics\n \n Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.\n Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.\n \n Contact:\n \n \n For Investors:\n \n Vivian Wu of Nektar Therapeutics628-895-0661\n \n For Media:\n \n Jonathan PappasLifeSci [email protected] \n \n View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-in-london-302600127.html\n SOURCE Nektar Th...